FDA approves Moderna’s first mRNA flu shot for adults 50+, enabling faster strain matching

The FDA approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based seasonal flu vaccine, for adults 50 and older, based on phase 3 data showing superior protection against flu-like illness versus standard vaccines; accelerated approval for 65+, with post‑approval confirmatory data required. The vaccine can be produced more quickly to better match evolving influenza strains, potentially adding an important option without replacing existing vaccines; common vaccine side effects apply, and availability is anticipated for the 2026–2027 season.